Literature DB >> 11873082

HIV-1 infection in individuals with the CCR5-Delta32/Delta32 genotype: acquisition of syncytium-inducing virus at seroconversion.

Haynes W Sheppard1, Connie Celum, Nelson L Michael, Stephen O'Brien, Michael Dean, Mary Carrington, Dale Dondero, Susan P Buchbinder.   

Abstract

Homozygosity for the 32 base-pair deletion (Delta32/Delta32) in the CCR5 coreceptor gene is associated with incomplete HIV-1 resistance. Six HIV-1-infected Delta32/Delta32 patients have been reported. We report 2 additional Delta32/Delta32-infected individuals, among 106 seroconverters in a vaccine preparedness study. Like the previous 6, these individuals experienced rapid CD4 decline. However, taken together, the 8 patients have neither uniformly high virus load nor rapid progression to AIDS. We obtained five virus isolates from 1 patient at 5, 6, 7, 10, and 12 months after the estimated time of infection. The earliest isolate exhibits the syncytium-inducing (SI) phenotype and exclusive use of the CXCR4 coreceptor, suggesting acquisition of HIV-1 through this coreceptor. Of the remaining 104 seroconverters, 8 were CCR5-Delta32/+ and 96 were CCR5-+/+. Three CCR5-+/+ seroconverters who showed the uncommon pattern of early SI virus and rapid CD4 decline had uniformly high viral load and more heterogeneous coreceptor usage. These results further support the conclusion that Delta32-mediated resistance is incomplete and is associated with acquisition of exclusively-X4 variants of HIV-1. The pathogenic potential of these viruses may be different from late-stage X4 virus or early X4 virus acquired by individuals with other CCR5 genotypes.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11873082     DOI: 10.1097/00126334-200203010-00013

Source DB:  PubMed          Journal:  J Acquir Immune Defic Syndr        ISSN: 1525-4135            Impact factor:   3.731


  34 in total

1.  R5 human immunodeficiency virus type 1 (HIV-1) replicates more efficiently in primary CD4+ T-cell cultures than X4 HIV-1.

Authors:  Becky Schweighardt; Ann-Marie Roy; Duncan A Meiklejohn; Edward J Grace; Walter J Moretto; Jonas J Heymann; Douglas F Nixon
Journal:  J Virol       Date:  2004-09       Impact factor: 5.103

Review 2.  The molecular mechanism of human resistance to HIV-1 infection in persistently infected individuals--a review, hypothesis and implications.

Authors:  Yechiel Becker
Journal:  Virus Genes       Date:  2005-08       Impact factor: 2.332

Review 3.  HIV and the chemokine system: 10 years later.

Authors:  Paolo Lusso
Journal:  EMBO J       Date:  2006-01-26       Impact factor: 11.598

4.  CCR5Delta32 59537-G/A promoter polymorphism is associated with low translational efficiency and the loss of CCR5Delta32 protective effects.

Authors:  Qingwen Jin; Lokesh Agrawal; L Meyer; R Tubiana; Ioannis Theodorou; Ghalib Alkhatib
Journal:  J Virol       Date:  2007-12-19       Impact factor: 5.103

5.  Counterpoint: Cord blood stem cell therapy for acquired immune deficiency syndrome.

Authors:  Ghalib Alkhatib
Journal:  Stem Cells Dev       Date:  2009 Jan-Feb       Impact factor: 3.272

6.  The degree of HIV-1 amino acid variability is strictly related to different disease progression rates.

Authors:  Rossana Scutari; Monica Faieta; Roberta D'Arrigo; Lavinia Fabeni; Cristina Mussini; Andrea Cossarizza; Claudio Casoli; Carlo Federico Perno; Valentina Svicher; Claudia Alteri; Stefano Aquaro
Journal:  Virus Genes       Date:  2018-05-17       Impact factor: 2.332

7.  Influence of CCR5 and CCR2 genetic variants in the resistance/susceptibility to HIV in serodiscordant couples from Colombia.

Authors:  Wildeman Zapata; Wbeimar Aguilar-Jiménez; Nicolás Pineda-Trujillo; Winston Rojas; Hernando Estrada; María T Rugeles
Journal:  AIDS Res Hum Retroviruses       Date:  2013-11-09       Impact factor: 2.205

8.  Genetic and functional analysis of R5X4 human immunodeficiency virus type 1 envelope glycoproteins derived from two individuals homozygous for the CCR5delta32 allele.

Authors:  Lachlan Gray; Melissa J Churchill; Niamh Keane; Jasminka Sterjovski; Anne M Ellett; Damian F J Purcell; Pantelis Poumbourios; Chenda Kol; Bin Wang; Nitin K Saksena; Steven L Wesselingh; Patricia Price; Martyn French; Dana Gabuzda; Paul R Gorry
Journal:  J Virol       Date:  2006-04       Impact factor: 5.103

9.  Significantly reduced CCR5-tropic HIV-1 replication in vitro in cells from subjects previously immunized with Vaccinia Virus.

Authors:  Raymond S Weinstein; Michael M Weinstein; Kenneth Alibek; Michael I Bukrinsky; Beda Brichacek
Journal:  BMC Immunol       Date:  2010-05-18       Impact factor: 3.615

10.  Contribution of immunological and virological factors to extremely severe primary HIV type 1 infection.

Authors:  Judith Dalmau; Maria Carmen Puertas; Marta Azuara; Ana Mariño; Nicole Frahm; Beatriz Mothe; Nuria Izquierdo-Useros; Maria José Buzón; Roger Paredes; Lourdes Matas; Todd M Allen; Christian Brander; Carlos Rodrigo; Bonaventura Clotet; Javier Martinez-Picado
Journal:  Clin Infect Dis       Date:  2009-01-15       Impact factor: 9.079

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.